logo

Critical Limb Ischemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Treatment Type (Devices, Medication and Surgeries) and by Geography.

Home Industry Reports Healthcare Critical Limb Ischemia Treatment Market - Growth, Trends, COVID-19 Impact, and F ...

Market Snapshot

Critical Limb Ischemia Treatment Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The critical limb ischemia treatment market studied was projected to grow with a CAGR of nearly 8.3% over the forecast period. The major factor attributing to the growth of the market is the increasing prevalence of critical limb ischemia. The key factors responsible for critical limb ischemia disease are increasing geriatric population, who are more vulnerable to the development of these conditions, and others include diabetes, obesity, sedentary lifestyle, smoking, and increased blood pressure. Untreated critical limb ischemia can lead to amputation of the specific limb. The growing incidence of critical limb ischemia is anticipated to drive the demand for its treatment, which, in line, is projected to propel the growth of the critical limb ischemia treatment market globally. Furthermore, the growing investments in research and development programs by the medical devices and pharmaceutical companies are boosting the market growth. However, drug failure and drug recalls are the major drawbacks for market growth.

Scope of the Report

As per the scope of the report critical limb ischemia is a chronic disease of peripheral arteries, in which chronic inflammation associated with atherosclerosis causes shortened flow of blood and oxygen to the legs, hands, and feet. This report is segmented by treatment type and by geography.

By Treatment Type
Devices
Embolic Protection Devices
Peripheral Dilatation Systems
Medications
Antiplatelet Drugs
Antihypertensive Agents
Lipid-lowering Agents
Others
Surgery
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Medications Segment is expected to Grow at a Faster Rate over the Forecast Period

  • The medications segment of the critical limb ischemia treatment market includes antihypertensive agents, antiplatelet drugs, antithrombotic agents, lipid-lowering agents, and others.
  • In critical limb ischemia patients who are not flexible for surgical or endovascular revascularization or patients with whom revascularisation attempts have been ineffective, medication is the only way to reduce the pain and treat the patients. Several studies have shown that medication reduced ischaemic rest pain, ulcer size and the need for amputation.
  • As the geriatric population increases the patient pool also increases which in turn boosts the market growth.
Age above 60

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall critical limb ischemia (CIL) treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of CIL patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. The United States holds the largest share of the market. The United States has a unique healthcare system among developed countries. However, the cost of hospitals is very high in the country; the government or private insurance covers it. The rising prevalence of CIL and the increasing geriatric population in the country are the prime factors responsible for the growth of the market in the country.

Autoimmune Treatment

Competitive Landscape

The critical limb ischemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently domianting the market are Medtronic plc, Abbott Laboratories, Rexgenero Ltd., LimFlow SA, Cardiovascular Systems, Inc., and ThermoGenesis Holdings, Inc

Critical Limb Ischemia Treatment Market

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in prevalence of Critical Limb Ischemia

      2. 4.2.2 Improvement in health care infrastructure

    3. 4.3 Market Restraints

      1. 4.3.1 Drug Failure and Drug Recalls

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Devices

        1. 5.1.1.1 Embolic Protection Devices

        2. 5.1.1.2 Peripheral Dilatation Systems

      2. 5.1.2 Medications

        1. 5.1.2.1 Antiplatelet Drugs

        2. 5.1.2.2 Antihypertensive Agents

        3. 5.1.2.3 Lipid-lowering Agents

        4. 5.1.2.4 Others

      3. 5.1.3 Surgery

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Medtronic plc

      2. 6.1.2 LimFlow SA

      3. 6.1.3 Cynata Therapeutics Ltd

      4. 6.1.4 Cardiovascular Systems, Inc.

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 Abbott Laboratories

      7. 6.1.7 Rexgenero Ltd.

      8. 6.1.8 ThermoGenesis Holdings, Inc

      9. 6.1.9 Teva Pharmaceuticals

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Critical Limb Ischemia Treatment Market market is studied from 2018 - 2026.

The Critical Limb Ischemia Treatment Market is growing at a CAGR of 8.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Medtronic plc, LimFlow SA, Cardiovascular Systems, Inc, Eli Lilly and Company, Abbott Laboratories are the major companies operating in Critical Limb Ischemia Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!